The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	None	Entity Type
0001697532	Applied Thera	peutics Inc.	X Corporation
Name of Issuer			Limited Partnership
Applied Therapeutics, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Org	ganization		General Partnership
DELAWARE			Business Trust
Year of Incorporation/Organizati	ion		
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Spe	cify Year)		
Yet to Be Formed	,		
recto be remined			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Applied Therapeutics, Inc.			
Street Address 1		Street Address 2	
545 FIFTH AVENUE, SUITE 1400	0		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
NEW YORK	NEW YORK	10017	212-220-9226
3. Related Persons			
	F:		
Last Name	First Name		Middle Name
Shendelman	Shoshana		
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400			
City	State/Province/Co	untry	ZIP/PostalCode
New York	NEW YORK		10017
Relationship: X Executive Office	cer X Director Promoter		
Clarification of Response (if Nec	essary):		
President and Chief Executive Office	cer		
Last Name	First Name		Middle Name
Perfetti	Riccardo		
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400			
City	State/Province/Co	untry	ZIP/PostalCode
New York	NEW YORK		10017
Relationship: X Executive Office	cer Director Promoter		
Clarification of Response (if Nec	essary):		
Chief Medical Officer			
Last Namo	First Name		Middle Name
Last Name Hansard	Adam		iviluale ivalitie
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400	Ctata/Drawings/0-	untn	ZID/DestalCade
City Nov. Vod.	State/Province/Co	uriu y	ZIP/PostalCode
New York	NEW YORK		10017

Relationship: X Executive Officer D	irector Promoter		
Clarification of Response (if Necessary):			
Chief Commercial Officer			
Last Name	First Name	Middle Name	
Funtleyder	Les		
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400			
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10017	
Relationship: X Executive Officer X D		10017	
Clarification of Response (if Necessary):	_		
Chief Financial Officer and Director			
Last Name	First Name	Middle Name	
Thorpe	Catherine		
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400			
City	State/Province/Country	ZIP/PostalCode	
	•		
New York	NEW YORK	10017	
Relationship: X Executive Officer D	irector Promoter		
Clarification of Response (if Necessary):			
Chief Accounting Officer			
Last Name	First Name	Middle Name	
Kanter	Stacy	J.	
Street Address 1	Street Address 2	••	
	Street Address 2		
545 Fifth Avenue, Suite 1400	0.1.15	710/0 / 10 /	
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10017	
Relationship: Executive Officer X D	irector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Lerner	Teena		
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400	Circle Address 2		
	Otata (Durania a a 10 annata)	71D/D t - 10 t -	
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10017	
Relationship: Executive Officer X D	irector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Marcus	Joel	S.	
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400			
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10017	
		1001/	
Relationship: Executive Officer X D	irector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Skyler	Jay	S.	
Street Address 1	Street Address 2		
545 Fifth Avenue, Suite 1400			
	State/Dravings/Country	7ID/DoctolCodo	
City	State/Province/Country	ZIP/PostalCode	

	EW YORK 10017	
Relationship: Executive Officer X Directo	r Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		
Agriculture	Health Care Retailing	
Banking & Financial Services	X Biotechnology Restaurants	
Commercial Banking Insurance	Health Insurance Technology	
Investing	Hospitals & Physicians Computers	
Investing Investment Banking	Pharmaceuticals Telecommunications	
Pooled Investment Fund	Other Health Care Other Technology	
Is the issuer registered as	Manufacturing Travel	
an investment company under	Real Estate Airports	
the Investment Company Act of 1940?	Commercial Lodging & Conventions	
Yes No	Construction	
Other Banking & Financial Services	DEITS & Finance	
Business Services	U Otner Travel	
Energy	Residential Other	
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Value Range	
No Revenues	No Aggregate Net Asset Value	
\$1 - \$1,000,000	\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000	\$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000	
\$25,000,001 -	二	
\$100,000,000	\$50,000,001 - \$100,000,000	
Over \$100,000,000	Over \$100,000,000	
X Decline to Disclose	Decline to Disclose	
Not Applicable	Not Applicable	
6. Federal Exemption(s) and Exclusion(s) C	claimed (select all that apply)	
	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1) Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)(2) Section 3(c)(10)	
Rule 504 (b)(1)(ii)	Section 3(c)(3) Section 3(c)(11)	
Rule 504 (b)(1)(iii)	Section 3(c)(4) Section 3(c)(12)	
X Rule 506(b)	Section 3(c)(5) Section 3(c)(13)	
Rule 506(c) Securities Act Section 4(a)(5)		
	Section 3(c)(6) Section 3(c)(14)	
	Section 3(c)(7)	
7. Type of Filing		
New Notice Date of First Sale 2024-02-27	First Sale Yet to Occur	

Amendment		
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
 X Equity Debt X Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Right to Acquire Security 	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other Other Other	
10. Business Combination Transaction		
Is this offering being made in connection with a business combine merger, acquisition or exchange offer?	nation transaction, such as a $\qquad \qquad \qquad \qquad \qquad \boxed{ \ \ }$ Yes $\boxed{ X \ \ }$ No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 US	D	
12. Sales Compensation		
Recipient UBS Securities LLC (Associated) Broker or Dealer X None None Street Address 1 1285 Avenue of the Americas City New York State(s) of Solicitation (select all that apply) Check "All States" or check individual States CALIFORNIA COLORADO CONNECTICUT FLORIDA ILLINOIS MARYLAND MASSACHUSETTS NEW JERSEY NEW YORK PENNSYLVANIA UTAH	Recipient CRD Number None None None Street Address 2 State/Province/Country NEW YORK Foreign/non-US	ZIP/Postal Code 10019
Recipient Leerink Partners LLC (Associated) Broker or Dealer X None None Street Address 1 53 State Street, 40th Floor City Boston State(s) of Solicitation (select all that apply) Check "All States" or check individual States CALIFORNIA COLORADO CONNECTICUT	Recipient CRD Number None None None Street Address 2 State/Province/Country MASSACHUSETTS Foreign/non-US	ZIP/Postal Code 02109

FLORIDA IILLINOIS MARYLAND MASSACHUSETTS NEW JERSEY NEW YORK PENNSYLVANIA		
UTAH		
Recipient	Recipient CRD Number None	
RBC Capital Markets, LLC	31194	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbf{X}}$ None	
None	None	
Street Address 1	Street Address 2	
3 World Financial Center City	200 Vesey Street State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10281
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
CALIFORNIA COLORADO CONNECTICUT FLORIDA IILLINOIS MARYLAND MASSACHUSETTS NEW JERSEY NEW YORK PENNSYLVANIA UTAH		
Recipient	Recipient CRD Number None	
Recipient Robert W. Baird & Co. Inc.	Recipient CRD Number None	
·	· 🗀	
Robert W. Baird & Co. Inc.	8158	
Robert W. Baird & Co. Inc. (Associated) Broker or Dealer X None None Street Address 1	8158 (Associated) Broker or Dealer CRD Number X None	
Robert W. Baird & Co. Inc. (Associated) Broker or Dealer X None None Street Address 1 777 E. Wisconsin Avenue	8158 (Associated) Broker or Dealer CRD Number X None None Street Address 2	7ID/Doctol Code
Robert W. Baird & Co. Inc. (Associated) Broker or Dealer X None None Street Address 1 777 E. Wisconsin Avenue City	8158 (Associated) Broker or Dealer CRD Number X None None Street Address 2 State/Province/Country	ZIP/Postal Code
Robert W. Baird & Co. Inc. (Associated) Broker or Dealer X None None Street Address 1 777 E. Wisconsin Avenue City Milwaukee State(s) of Solicitation (select all that apply)	8158 (Associated) Broker or Dealer CRD Number X None None Street Address 2	ZIP/Postal Code 53202
Robert W. Baird & Co. Inc. (Associated) Broker or Dealer X None None Street Address 1 777 E. Wisconsin Avenue City Milwaukee	8158 (Associated) Broker or Dealer CRD Number X None None Street Address 2 State/Province/Country WISCONSIN	
Robert W. Baird & Co. Inc. (Associated) Broker or Dealer X None None Street Address 1 777 E. Wisconsin Avenue City Milwaukee State(s) of Solicitation (select all that apply) Check "All States" or check individual States CALIFORNIA COLORADO CONNECTICUT FLORIDA ILLINOIS MARYLAND MASSACHUSETTS NEW JERSEY NEW YORK PENNSYLVANIA UTAH	8158 (Associated) Broker or Dealer CRD Number X None None Street Address 2 State/Province/Country WISCONSIN	

Total Amount Sold \$99,997,998 USD
Total Remaining to be Sold \$0 USD or Indefinite
Clarification of Response (if Necessary):
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$7,499,850 USD X Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Applied Therapeutics, Inc.	/s/ Shoshana Shendelman	Shoshana Shendelman	Chief Executive Officer	2024-03-13

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.